<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib31">
 <label>31</label>
 <element-citation publication-type="journal" id="sref31">
  <person-group person-group-type="author">
   <name>
    <surname>Wedemeyer</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Schoeneweis</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Bogomolov</surname>
    <given-names>P.O.</given-names>
   </name>
   <name>
    <surname>Voronkova</surname>
    <given-names>N.V.</given-names>
   </name>
   <name>
    <surname>Chulanov</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Stepanova</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with Peg-Interferon alpha 2a in patients with chronic HBV/HDV co-infection</article-title>
  <source>Hepatology</source>
  <volume>68</volume>
  <year>2018</year>
  <fpage>11A</fpage>
 </element-citation>
</ref>
